Arcus Biosciences, Inc.: financial statements

RCUSNYSEHealthcare · Pharmaceutical Preparations

Price

$16.39

November 17, 2026Market cap $2.4B

What Ploutos Investor adds for Arcus Biosciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 9 fiscal years, from 2017
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Revenue

+45.3% a year over 2 years

Line202320242025Average a year
Revenue $117M$258M$247M+45.3%
Operating income -$340M-$330M-$386M
Net income -$307M-$283M-$353M
Earnings per share -$4.15-$3.14-$3.29
Earnings per share, basic -$4.15-$3.14-$3.29
Margins
Operating margin -290.6%-127.9%-156.3%
Net margin -262.4%-109.7%-142.9%

Financial statements

RCUS's revenue, profits and cash flows from 2017 to 2022, 6 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

By segment

Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.

  • 2023: License And Development Services $80M, Other Collaboration Revenue $37M
  • 2024: License And Development Services $222M, Other Collaboration Revenue $36M
  • 2025: License And Development Services $221M, Other Collaboration Revenue $26M
Product202320242025Share 2025
License And Development Services$80M$222M$221M89%
Other Collaboration Revenue$37M$36M$26M11%

By segment

RCUS's revenue by product line from 2018 to 2022, 5 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

From the XBRL of 8 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$99M Leases0.1% Effective tax rate

The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

Leases

Dec 31, 2025

Operating leases

$99M

Finance leases

–

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

21.0%

Effective rate

0.1%

-20.9 pts

The company paid 0.1% in tax on its profit, 20.9 points below the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

Change in valuation allowance

-26.1 pts

Difference the filing does not itemize

+5.2 pts

Effective rate

0.1%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

Claims ahead of shareholders

What stands between the business and its shareholders besides the debt, and the financial assets on the other side, from the latest balance sheet.

$64M securities and stakes

Other than debt, no claim large enough to list ranks ahead of the shares.

On the other side, it holds $64M of long-term securities and stakes in other companies, at the value in its accounts, about 2.7% of the market value.

On the other side

at Sep 30, 2026
$64M

From the balance sheet of September 30, 2026. The retirement and environmental lines and the pension deficit come from the latest annual report when the quarter's filing does not state them, each with its own date. Market value at the price of November 17, 2026. A line is listed when it is at least 0.5% of the market value. A description of the balance sheet, not a valuation.

The full analysis

What do Arcus Biosciences's filings show?

These are Arcus Biosciences's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about RCUS's financials

Didn't find what you were looking for?

Ask us
How much revenue did RCUS have in 2025?

Arcus Biosciences had revenue of $247M and net income of -$353M in fiscal 2025, a net margin of -142.9%.

How much debt does RCUS have?

On December 31, 2025 Arcus Biosciences had total assets of $1.1B, debt of $99M and shareholders' equity of $631M.

How much free cash flow does RCUS have?

In fiscal 2025 Arcus Biosciences had cash from operations of -$482M and spent $2.0M on capital expenditure, leaving -$484M of free cash flow.

Where are the figures from?

From Arcus Biosciences, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.